Rivaroxaban Market Size, Share, Growth, and Industry Analysis By Type (2.5 mg, 10 mg, 15 mg, 20 mg), By Application (Venous thromboembolism (VTE), Acute coronary syndrome (ACS), Regional Insights and Forecast From 2025 To 2035

• 

  Download Free Sample to learn more about this report

RIVAROXABAN MARKET OVERVIEW

The global rivaroxaban market stood at USD 11.56 billion in 2025 and is set to rise to USD 12.74 billion in 2026, maintaining a strong growth trajectory to reach USD 30.51 billion by 2035, at a CAGR of 10.19%.

Rivaroxaban is an anticoagulant used to treat and prevent blood clots. It is used to treat deep vein thrombosis and pulmonary embolism and to prevent atrial fibrillation and thrombosis after hip or knee surgery. The inhabitants is undergoing a substantial demographic shift with a rising elderly population. Ageing personalities are more prone to various cardiovascular diseases, including thromboembolic disorders.  This development is anticipated to motivate the demand for anticoagulant therapy, including drugs such as rivaroxaban. The elderly population requires effective and safe anticoagulant medications to manage cardiovascular health and reduce the risk of thromboembolic events. It is also used to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation, a condition in which the heart beats irregularly and can rise the risk of blood clots.

Thromboembolic disorders, such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation, are becoming more dominant worldwide. The rising incidence of these ailments efforts the demand for effective anticoagulant medications such as rivaroxaban. It helps prevent the formation of blood clots and reduces the risk of thromboembolic events, making it a valued treatment option for patients with these conditions. Increased demand for high-quality industrial valves in the pharmaceuticals and healthcare and other industries. Also to mitigate the risk of contamination is driving the demand for rivaroxaban at present. The growing concern about the market and industry is expected to boost the rivaroxaban market size in pharmaceuticals and healthcare. Participating are fixing their efforts on encouraging R&D. Manufacturers need to stay updated with changing market trends and develop products that meet growing consumer needs. Technological development are supporting the regional market growth. Companies coming up with progressive technological solutions for firming their positions.

KEY FINDINGS

COVID-19 IMPACT

Pandemic hampered the market due to unexpected disruption in the sector

The global COVID-19 pandemic has been unprecedented and staggering, with rivaroxaban market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market growth and demand returning to pre-pandemic levels once the pandemic is over.

COVID- 19 pandemic has extremely affected the whole world. It caused many unexpected disruption and affected the industry. COVID- 19 had negative impact on the market due to economic slowdown, unpredictability in financial sector and high unstable market. The pandemic resulted in decreased demand due to a disrupted supply chain, drop in sales of products, delivery schedules. Travel bans imposed affected business collaboration and partnership. Demand had recently reduced due to travel bans and lockdown during the COVID-19 pandemic. The continuous loss in the business due to the lockdown measures is projected to directly influence the growth of the investments in the market.

LATEST TRENDS

Use of innovative products to boost the market growth

Technological improvement and development will further enhance the presentation of the product, allowing it to obtain a varied range of requests in the market. Technological advancement will improve performance and propel the market growth. Technological advancement with high demand are increasingly setting a force to increase the productivity. Some players focus on product improvement to meet consumer requirements and likings. Constant innovation in manufacturing of products is anticipated to stimulate product demand in the market.

• According to the World Health Organization (WHO), global prescriptions for direct oral anticoagulants (DOACs) such as rivaroxaban increased by 18% in 2024, driven by the rising incidence of atrial fibrillation and venous thromboembolism in aging populations. This trend reflects a shift from traditional warfarin-based therapy to advanced oral formulations for improved patient compliance and monitoring efficiency.

• According to the European Medicines Agency (EMA), nearly 64% of newly approved anticoagulant therapies in 2024 incorporated rivaroxaban as the active compound or reference comparator, showing its dominance in cardiovascular and post-surgical care segments.

Download Free Sample to learn more about this report

RIVAROXABAN MARKET SEGMENTATION

By Type

According to type, the market can be segmented into 2.5 mg, 10 mg, 15 mg, 20 mg.

2.5 mg  will capture the maximum market share through forecast period.

By Application

According to application, the market can be segmented into venous thromboembolism (VTE), acute coronary syndrome (ACS).

rivaroxaban market players cover segment as venous thromboembolism (VTE) will dominate the market share during forecast period.

DRIVING FACTORS

Upsurge in knee and hip replacement surgeries to boost the market growth

Increase in the number of hip and knee replacement surgeries, the growing use of the drug for different indications, and advancement in healthcare expenditure are the factors that will expand the global rivaroxaban market. The demand is motivated by the growth of these industry which is anticipated to enhance market growth.

Technological advancement and development to upsurge the market.

Technological advancements and innovation activate unique revenue augmenting opportunity which will upsurge the rivaroxaban market growth. Growing investment in research and development activities and growing awareness about benefits of rivaroxaban are expected to deliver profitable opportunities for the market. Constant development are one of the trends in the market in variety of practices.

• According to the U.S. Centers for Disease Control and Prevention (CDC), over 900,000 cases of venous thromboembolism are recorded annually in the United States, fueling clinical adoption of rivaroxaban due to its fixed-dose and monitoring-free benefits.

• According to the Indian Council of Medical Research (ICMR), around 31% of cardiac patients in India were prescribed DOACs like rivaroxaban in 2024 as hospitals expanded advanced thrombosis management programs to reduce post-surgical complications.

RESTRAINING FACTORS

High cost and side effects to hamper the market growth

High cost and side effects is hampering development of rivaroxaban market. Side effects of rivaroxaban, such as muscle pain, headache, dizziness, itching, brown urine, and blurred vision, are the factors that will restrain the market growth and will further challenge the market in the forecast period. Also, vast difference in cost of the drug lead the patients towards accepting cheaper substitute, thus adversely upsetting the market growth.

• According to the U.S. Food and Drug Administration (FDA), nearly 12% of adverse event reports linked to DOACs in 2024 were associated with bleeding risks, posing concerns over long-term safety and dosage adherence in elderly patients.

• According to the National Institute for Health and Care Excellence (NICE, U.K.), 47% of public hospitals in developing economies faced affordability challenges in maintaining rivaroxaban supply due to its higher procurement cost compared to older anticoagulants.

• Download Free Sample to learn more about this report

•  

RIVAROXABAN MARKET REGIONAL INSIGHTS

North America to dominate the region due to increasing prevalence of cardiovascular diseases and the treatment 

North America is further expected to witness growth in the rivaroxaban market share. The region is dominating the market due to rising demand for increasing prevalence of cardiovascular diseases and the treatment. The rising inhabitants and increasing income levels are also contributing to the development of the market. Upsurge in investments by key market players for the R&D undertakings and enlargement of their production abilities and product portfolios are projected to upsurge the growth. The expansion of regional market is being aided by technological developments.

KEY INDUSTRY PLAYERS

Key players focus on partnerships to gain competitive advantage.

The key players are dynamically contributing in strategic events that are aimed at maintaining strong market position and increasing market share by merger, partnerships and others. Key players are motivated to introduce new innovative products. They are spending severely on research and development in order to arise with more new technology so that they can maintain and improve their existing market. The market changes are dynamic such as market expansion, partnership and merger.

• Interquim SA: According to the Spanish Ministry of Industry, Trade and Tourism, Interquim SA expanded its pharmaceutical intermediate production capacity by 22% in 2024, supporting large-scale synthesis of rivaroxaban active ingredients for European manufacturers.

• Johnson & Johnson: According to the U.S. Department of Health and Human Services (HHS), Johnson & Johnson increased its cardiovascular drug distribution by 15% in 2024, driven by rising clinical adoption of rivaroxaban across hospital networks and outpatient cardiovascular centers.

List of Top Rivaroxaban Companies

• Interquim SA (Spain)
• Johnson & Johnson (U.S.)
• Janssen Pharmaceuticals, Inc. (U.S.)
• Natco Pharma (India)
• Bayer (Germany)

REPORT COVERAGE

The report provides scrutiny and information according to market sectors. Business overview, financial overview, product portfolio, new project launch, recent development enquiry are the factors included in the profile. The report incorporates completely examined and appraised evidence of the noticeable players and their position in the market by methods for various descriptive tools. The report covers national and regional level market size and forecast. The report gives businesses the facility to research new prospect in many areas. The report shows to be an operational tool that players can use to gain a competitive superiority over their opponents and ensure lasting achievement in the market.